{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Disease flare is determined by the Physician's global assessment of autoinflammatory disease activity, assessment of skin disease and inflammation markers. Disease Flare = the C-reactive protein and/or serum amyloid A (SAA) \\> 30 mg/L and either a PGA \\> minimal, or PGA equal to minimal and \\> minimal SD.","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"},{"description":"Placebo subcutaneous injection every 8 weeks.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"32 weeks after study start","title":"Number of Participants Who Experienced a Disease Flare in Part II","type":"PRIMARY","unitOfMeasure":"Participants"}